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ABSTRACT
Introduction The management of small pancreatic 
neuroendocrine neoplasms (PNENs) remains controversial. 
The standard treatment for PNENs is surgical resection; 
however, invasiveness of surgical procedure remains 
higher and the incidence of postoperative adverse events 
is still high. Recently, the efficacy and safety of endoscopic 
ultrasonography (EUS)- guided ethanol injection for small 
PNENs has been preliminarily demonstrated. Thus, a 
multicentre prospective study is being conducted to 
evaluate the efficacy and safety of EUS- guided ethanol 
injection therapy for small PNENs.
Methods and analysis The major eligibility criteria are the 
presence of pathologically diagnosed grade (G) 1 tumour, 
a tumour size of ≤15 mm and non- functional PNEN or 
insulinoma. For treatment, we will use a 25- gauge needle 
and pure ethanol. Contrast- enhanced CT (CE- CT) will be 
performed on postoperative day 3–5, and if enhanced areas 
of the tumour are still apparent, an additional session is 
scheduled during the same hospitalisation period. We set 
the total amount of ethanol per session to 2 mL. To evaluate 
the efficacy and safety, CE- CT will be performed at 1 and 
6 months after treatment. The primary endpoint is the 
percentage of subjects who achieved all of the following 
evaluated points. Efficacy will be evaluated based on the 
achievement of complete ablation (defined as no enhanced 
area within the tumour on CE- CT) at 1 and 6 months. 
Safety will be evaluated based on the avoidance of severe 
adverse events within 1 month after treatment, continuing 
severe pancreatic fistula at 1 month after treatment and 
the incidence and/or exacerbation of diabetes mellitus at 6 
months after treatment.
Ethics and dissemination This protocol has been 
approved by Okayama University Certified Review Board 
(approval number. CRB19-007). The results will be 
submitted to peer- reviewed journals and will be presented 
at international conferences.
Trial registration number jRCTs061200016.
INTRODUCTION
Pancreatic neuroendocrine neoplasms 
(PNENs) are fairly rare, accounting for 
1%–2% of primary pancreatic malignan-
cies.1 However, the incidence of PNENs has 
increased substantially because of the wide-
spread use of advanced endoscopic and 
radiological imaging techniques.2
The treatment methods for PNENs depend 
on the hormone- related symptoms and 
tumour size.3 4 For patients with symptom-
atic disease or tumours of >2 cm in diameter, 
surgical resection is the standard of care. 
However, the optimal treatment approach for 
patients with non- functional, small PNENs 
(≤2 cm in diameter) is controversial. Sadot 
et al4 reported the outcomes of observation 
versus resection for small asymptomatic 
PNENs. In their report, the observation was 
recommended for 104 patients (observation 
group), and these patients were matched to 
77 patients in a resection group based on 
tumour size on initial imaging (the median 
tumour size in the observation and resection 
Strengths and limitations of this study
 ► This is the first prospective multicentre confirmato-
ry clinical study conducted to investigate the effi-
cacy and safety of an endoscopic ultrasonography 
(EUS)- guided ethanol injection therapy in patients 
with small grade 1 pancreatic neuroendocrine neo-
plasms (PNENs).
 ► This proposed study investigates EUS- guided ther-
apy as a less invasive treatment approach to the 
treatment of small PNENs in patients without lymph 
node metastasis in comparison to surgical treatment 
in terms of both efficacy and safety.
 ► This study was conducted in a single arm with 
short- term follow- up period. The follow- up period 
was not sufficient to assess the efficacy in prevent-
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groups was 12 mm and 14 mm, respectively). The 5- year 
overall survival rate of the observation and resection 
groups were 99% (95% CI: 95% to 100%) and 91% (95% 
CI: 84% to 97%), respectively with a median follow- up 
period of 44 months and 57 months, respectively; There 
were no significant differences between the two groups 
(log- rank, p=0.3), and no patients in either group died 
from the disease. However, within the observation group, 
26 of the 104 patients (25%) underwent subsequent 
tumour resection after a median observation interval 
of 30 months (range, 7–135 months) (patient’s prefer-
ence, n=10 (38%); increasing tumour size, n=8 (31%); 
physician’s preference, n=7 (27%); and development of 
pancreatic duct dilatation, n=1 (4%)). Although obser-
vation for stable, small, incidentally discovered PNEN is 
considered reasonable for selected patients, it is unknown 
whether a tumour will be aggressive or not when it is 
small in size. Moreover, patients undergoing observation 
should be followed up at least once a year using CT or 
MRI with contrast medium.
The benefit of surgery must be balanced against poten-
tial postoperative complications.3–5 In a study of surgical 
resection for benign pancreatic tumours, the morbidity 
rates for pancreaticoduodenectomy (PD), distal pancre-
atectomy (DP) and parenchyma- preserving resection 
were reported to be 52%, 47% and 44%, respectively.5 
Furthermore, 18% of patients developed diabetes mellitus 
(DM) after PD and 14% developed DM after DP.5 These 
are just some of the problems associated with pancreatic 
surgery that leads to lower quality- of- life of the patient.
Recently, endoscopic ultrasonography (EUS)- guided 
ethanol ablation has been proposed for the treatment 
of patients with small PNENs who refuse surgery or who 
are poor surgical candidates.6–15 Using pure ethanol or 
ethanol–lipiodol emulsion,7 the complete ablation rate 
has been reported to be approximately 50% with a single 
session and up to 60%–80% with an additional session.6–8 
As for complications, mild pancreatitis occurred in a few 
patients required a large amount of ethanol (>2 mL) in 
one session even if the tumour size was less than 2 cm.6–15 
We previously described the efficacy and safety of sched-
uled early EUS- guided ethanol reinjection therapy for 
small PNENs.8 A total of five patients with pathologically- 
proven grade (G) 1 PNENs were treated; the median 
diameter of target lesion was 10 mm (range: 7–14 mm). Of 
these five patients, three underwent an additional session 
at 3 days after the first treatment. The median volume of 
ethanol injected per session was 0.8 mL (range: 0.3–1 mL), 
and the mean total volume was 1 mL (0.9–1.8 mL). 
Complete ablation (defined based on contrast- enhanced 
(CE)- CT at 1 month after treatment) was achieved in four 
of the five tumours (80%). During 1 year of follow- up, 
none of the patients reported any procedure- related 
adverse events, including the development of DM, and 
no patients showed tumour recurrence. The results indi-
cated that the use of a small amount of ethanol reduced 
the procedure- related adverse events, and that scheduled 
injection increased the complete ablation rate.
The advantages of EUS- guided therapy are that the 
reduction of complications can be expected in compar-
ison to surgical resection and that the pancreatic 
exocrine and endocrine functions can be preserved. On 
the other hand, EUS- guided therapy is associated with 
a limitation. Complete tumour ablation is determined 
based on thin slice CE- CT findings; however, it is some-
times difficult to demonstrate complete tumour elimi-
nation. Furthermore, long- term follow- up is required to 
prove the efficacy of EUS- guided treatment, and lymph 
node dissection cannot be performed. Thus, EUS- guided 
treatment should be limited to patients with a low risk of 
lymph node metastasis and small tumour size.
Hashim et al16 reported on the rate of lymph node 
metastasis of PNENs according to tumour size. They eval-
uated 136 patients who underwent surgical resection of 
PNENs with lymph node resection (surgical methods: DP, 
54%; PD, 41%; total pancreatectomy, 2%; nuclear exci-
sion, 2%). The lymph node metastasis rates were 12% 
(2/17) in patients with a tumour diameter of ≤10 mm, 
14.3% (3/22) in patients with a tumour diameter of 
11–15 mm and 40% (8/21) in patients with a tumour 
diameter of 16–20 mm. A logistic regression analysis 
was performed to determine factors associated with the 
frequency of lymph node metastasis: the frequency was 
higher in patients with larger tumours (>1.5 cm; OR=4.7), 
tumours of the head (in comparison to pancreatic body- 
tail (OR=2.8)), tumours with Ki-67 of >20% (OR=6.7) 
and tumours with lymphovascular invasion (OR=3.6) 
(p<0.05). Considering the risk of lymph node metastasis, 
tumour size ≤15 mm and pathologically G1 are suitable 
for EUS- guided therapy.
Therefore, we launched the current trial to assess 
the efficacy and safety of EUS- guided ethanol injection 




This study is conducted as a multicentre, single- arm, 
prospective, phase II study in six high- volume medical 
centres in Japan. Eligible patients with a PNEN will be 
treated by EUS- guided ethanol injection and followed 
up until 6 months after treatment. An overview of the 
protocol is shown in figure 1.
Endpoints
Primary endpoint
This study establishes a composite primary endpoint. 
The primary endpoint is the percentages of subjects who 
achieve all of the following evaluated points.
1. Efficacy:
 – Complete ablation on CE- CT at 1 and 6 months af-
ter treatment
2. Safety:
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 – Avoidance of severe pancreatic fistula at 1 month 
after treatment
 – Avoidance of the incidence and/or exacerbation of 
DM at 6 months after treatment
Secondary endpoints
The following secondary endpoints will be evaluated in 
two cohorts: Cohort 1 (tumour size ≤10 mm) and Cohort 
2 (tumour size 10–15 mm).
1. Safety:
 – Prevalence of total adverse events
 – Prevalence of device failures
 – Prevalence of conversion to surgery
 – Prevalence of severe adverse event within 1 month 
after procedure
 – Prevalence of severe pancreatic fistula at 1 month 
after procedure
 – Prevalence of DM exacerbation at 6 months after 
treatment.
2. Efficacy:
 – Complete ablation on CE- CT at 1 month after treat-
ment
 – Complete ablation on CE- CT at 6 months after 
treatment
 – Six- month overall survival.
The following endpoints will only be evaluated in 
patients with insulinoma.
1. Improvement of hypoglycaemic symptoms
2. Changes in serum levels of fasting blood glucose, insu-
lin and C peptide from before to after the procedure
Definition
Complete ablation is defined as the absence of enhanced 
areas within the tumour on arterial phase CE- CT imaging 
with a slice thickness of 1–2 mm. The CE- CT images will be 
reviewed independently by two expert gastroenterologists. 
If it is difficult to make a judgement by CE- CT, CE- EUS 
will be performed to assess the existence of enhanced 
areas within the tumour. Procedure- related adverse 
events will be evaluated based on American Society for 
Gastrointestinal Endoscopy (ASGE) guideline 2010,17 and 
other adverse events will be evaluated based on Common 
Terminology Criteria for Adverse Event (CTCAE) V.5.0. 
Severe adverse events are defined as moderate or higher 
in ASGE and grade 3 or higher in CTCAE. Severe pancre-
atic fistula is defined as continuing any treatment for 
pancreatic fistula (percutaneous or endoscopic drainage 
tube and/or medication) at 1 month after the procedure. 
DM is defined as a fasting blood glucose level of 126 mg/
dL or an occasional blood glucose level of 200 mg/dL and 
glycated haemoglobin (HbA1c) ≥6.5 (National Glycohe-
moglobin Standardisation Programme value). New- onset 
DM means that a patient without DM at the time of regis-
tration newly developed DM, and the exacerbation of DM 
means that a patient who did not meet the definition for 
DM at the time of registration starts or adds a medica-
tion for DM due to poor glycaemic control, or HbA1c is 
increased up to 0.2%.
Patient eligibility
The eligibility and exclusion criteria are shown in 
box 1. EUS- guided fine needle aspiration (FNA) will 
be performed to exclude the possibility of lymph node 
metastasis. A flow chart of suspicion of lymph node metas-
tasis on CE- CT is shown in figure 2.
Figure 1 A flow chart of the present study. CE- CT, contrast- 
enhanced CT; EUS, endoscopic ultrasonography.
Box 1 
Inclusion criteria
 ► Age 20–75 years.
 ► Patient who has given their fully informed consent.
 ► A diagnosis of a pancreatic neuroendocrine neoplasm (PNEN) with 
grade 1 confirmed pathologically by endoscopic ultrasonography- 
guided fine needle aspiration specimen (WHO 2017 classification).
 ► Tumour diameter ≤15 mm and well- enhanced tumour in the arterial 
phase on contrast enhanced- CT (CE- CT).
 ► A PNEN diagnosed as a non- functional tumour or an insulinoma.
Exclusion criteria
 ► Allergy to contrast media or ethanol.
 ► The distance between tumour and main pancreatic duct is ≤2 mm 
on radiographic images.
 ► Suspicion of lymph node metastasis or distant metastasis on CE- CT.
 ► Prothrombin time ≤50% or international normalised ratio ≥1.5.
 ► Platelet ≤50×109/L.
 ► Estimated glomerular filtration rate ≤30 mL/min.
 ► Administered ≥2 antithrombotic agents.
 ► Performance status ≥2.
 ► Being pregnant or possibly pregnant.
 ► Poor prognosis (<5 years) predicted.
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Study procedure
The procedure is performed with the patient in a prone 
or semi- prone position under conscious sedation using 
intravenous anaesthetic in the endoscopy room. For 
treatment, a 25- G fine- needle aspiration needle (EZ- shot 
3; Olympus Medical Systems, Tokyo, Japan) filled with 
ethanol is advanced into the tumour under EUS. Then, 
pure ethanol (Mylan Seiyaku, Tokyo, Japan) is injected 
until a hyperechoic blush extends to the edge of the 
tumour margin and the needle is kept inside the tumour 
for at least 1 min to avoid the backflow of ethanol. Once 
the needle is removed, we check for low- echoic areas of 
the tumour. If such areas are detected, ethanol is added 
to the site. For the sake of safety, the amount of ethanol 
per puncture is set to 1 mL, the total number of punc-
tures per session is set to 3, and the maximum volume of 
ethanol per session is set to 2 mL.
At 3–5 days after the treatment, CE- CT is performed 
to evaluate the tumour viability and procedure- related 
adverse events. If enhanced areas of the tumour are noted 
on postprocedural CE- CT, we will perform an additional 
ablation session during the same hospitalisation period. 
The patient is discharged 1 day after this additional 
session. If there are no enhanced areas of the tumour on 
postprocedural CE- CT, then the patient is discharged. 
Blood testing is performed at 2 hours postoperatively and 
on postoperative day 1.
Follow-up
Follow- up examinations are scheduled for 1, 3 and 6 
months to evaluate the general condition of the patient, 
and blood testing is performed. The patients are also 
scheduled to undergo follow- up CE- CT imaging at 1 and 
6 months after discharge. When incomplete ablation of 
the treated lesion is judged to have occurred based on 
follow- up CE- CT, salvage surgical resection will be consid-
ered to the patient.
Patient and public involvement
No patient involved.
Sample size calculation
A historical data set was analysed to evaluate surgical 
treatment in 23 patients with PNEN (≤15 mm in diam-
eter) who underwent treatment at Okayama University 
Hospital from November 2007 to January 2018. This 
data showed that 48% (11/23) of the patients met the 
composite primary endpoints; the local control rate for 
target lesion was 100% (23/23), the rate of severe adverse 
events (Clavien- Dindo grade III- IV) within 1 month after 
treatment was 35% (8/23), the rate of severe pancreatic 
fistula at 1 month after treatment was 35% (8/23) and 
the incidence of DM or the exacerbation of DM at 6 
months after treatment was 17% (4/23), respectively. In 
our previous pilot study of EUS- guided ethanol injection 
therapy, 75% (6/8) of the patients achieved the composite 
primary endpoints; the complete ablation rate at 1 and 6 
months was 75% (6/8), no patients experienced severe 
adverse events, no patients developed severe pancreatic 
fistula and no patients developed DM or experienced 
an exacerbation of DM. Thus, the null and alternative 
hypotheses are given below:
H0: PT=0.48
H1: PT=0.75
where PT is the anticipated composite primary endpoint 
after the study procedure. Against abovementioned back-
ground, 22 patients would provide a statistical power of 
80% to test the primary hypothesis at the two- sided signif-
icance level of 0.1. Considering non- compliance and/or 
dropout patients, 25 patients are recruited in total.
Statistical analysis
The data analysis is performed according to an intention- 
to- treat principle. Clopper- Pearson’s exact binomial test 
and CI estimation are applied for the primary endpoint 
and the secondary endpoints. The statistical significance 
level is set at 10% for the purpose of orphan disease regu-
latory filing, otherwise 5% (two- sided). All analyses are 
conducted with SAS software (SAS Institute).
ETHICS AND DISSEMINATION
Written informed consent from all the patients screened 
will be obtained before the procedures start. The study 
protocol has been approved by Okayama University Certi-
fied Review Board (approval number. CRB19-007) and 
registered in Japan Registry of Clinical Trial. Monitoring 
and auditing will be carried out throughout the trial. 
We will also establish an independent data monitoring 
committee consisting of three additional doctors who 
were not associated with the study to determine whether 
or not the study should continue if severe adverse events 
occur.
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